Product Pathways - Growth Factors/Cytokines
Human Interferon-α1 (hIFN-α1) #8927
|8927LC||50 µg (With Carrier)||---||In Stock||---|
|8927LF||50 µg (Carrier Free)||---||In Stock||---|
|8927SC||10 µg (With Carrier)||---||In Stock||---|
|8927SF||10 µg (Carrier Free)||---||In Stock||---|
Already purchased this product? Write a Review.
Recombinant human IFN-α1 (hIFN-α1) Cys24 - Asp189 (Accession # NP_076918) was produced in E. coli at Cell Signaling Technology.
Recombinant hIFN-α1 does not have a Met on the amino terminus and has a calculated MW of 19,386. DTT-reduced protein migrates as an 18 kDa polypeptide and non-reduced protein migrates as a 14 kDa polypeptide due to intramolecular cystines. The expected amino-terminal CDLPE of recombinant hIFN-α1 was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hIFN-α1. All lots are greater than 98% pure.
The bioactivity of hIFN-α1 was determined in a virus protection assay. The ED50 of each lot is between 20 - 60 pg/ml.
The purity of recombinant hIFN-α1 was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hIFN-α1 and staining overnight with Coomassie Blue.
The bioactivity of recombinant hIFN-α1 was determined in a virus protection assay. HeLa cells were pretreated with increasing concentrations of hIFN-α1 for 24 hours. Cells were then inoculated with encephalomyocarditis virus (EMCV) and incubated for an additional 48 hours. Surviving cells were then fixed and stained with crystal violet and the OD595 was determined.
Western blot analysis of extracts from HeLa cells, untreated or treated with hIFN-α1 for 15 minutes, using Phospho-Stat1 (Tyr701) Antibody #9171 (upper) and Stat1 Antibody #9172 (lower).
Less than 0.01 ng endotoxin/1 μg hIFN-α1.
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg hIFN-α1. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Interferon-α1 is a member of the Type I IFN (1) family best known for their antiviral activity. Most nucleated cells produce one or more Type I IFNs in response to viral infection (2). Secreted Type I IFN then induces viral protective responses in neighboring non-infected cells. Type I IFNs also enhance virus-induced apoptosis (3). Other IFN-α1 activities include enhancement of dendritic cell maturation and cytotoxic T cell activity (4). IFN-α1 binds to the IFN-αR1 and IFN-αR2 heterodimer (1). Intracellular signaling through the Jak/Stat pathway is best characterized (3). However, the PI3K, ERK, and p38 kinase pathways are also involved (5). The antiviral activities of the IFNs have led to their use in treating viral infections (4). Type I IFNs also appear to have an integral role in several autoimmune diseases (6).
- Nagai, T. et al. (2003) J Immunol 171, 5233-43.
- Stetson, D.B. and Medzhitov, R. (2006) Immunity 25, 373-81.
- Vilcek, J. (2006) Immunity 25, 343-8.
- Luft, T. et al. (2002) Int Immunol 14, 367-80.
- van Boxel-Dezaire, A.H. et al. (2006) Immunity 25, 361-72.
- Banchereau, J. and Pascual, V. (2006) Immunity 25, 383-92.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.